Key facts
- This page summarizes Michael S. Wyzga's Form 4 filing for Mereo BioPharma Group plc (MREO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2026, 16:30.
Michael S. Wyzga - 26 Feb 2026 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)
- Reporting relationship
- Director
- Issuer ticker
- MREO
- Reported as of
- 26 Feb 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2026, 16:30:08 UTC
- Prior SEC filing
- 05 Jan 2026
- Next SEC filing
- 11 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Christine Fox, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael S. Wyzga filed Form 4 for Mereo BioPharma Group plc (MREO) on 27 Feb 2026.
Change
- Previous filing in this sequence was filed on 05 Jan 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001201256
Primary reporting owner
WYZGA MICHAEL S
- Relationship
- Director
- Address
- C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, UNITED KINGDOM
- Signature
- /s/ Christine Fox, by power of attorney
- Signature date
- 27 Feb 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MREO
transaction
Derivative
Share Options (Right to buy)
Award
- Transaction value
- $0
- Shares
- +66,000
- Change %
- Price
- $0.000000
- Shares after
- 66,000
- Date
- 26 Feb 2026
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
- 66,000
- Exercise price
- $0.3900
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
Footnote F2
Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.